Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)143-144
Number of pages2
JournalInternational Journal of Advances in Rheumatology
Volume9
Issue number4
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Rheumatology

Cite this